The biosimilar workshop hosted by the US Food and Drug Administration and the Federal Trade Commission was a sold-out event, drawing a swarm of participants who spilled into an overflow room. While it generated red hot interest among stakeholders, the meeting mostly provided a snapshot of the current biosimilar market with oft-stated recommendations of what could be done to tear down barriers to biosimilar use.
But the 9 March workshop was still a landmark event, illustrating the commitment by FDA and the FTC to take...